Biolandia

[Biolandia @valueinvest01]

$IDYA Idorsia might hit 10$ faster thant I thought. Easy multi bagger .. don't miss the opportunity guys .

[Biolandia @valueinvest01]

Idorsia $IDIA is on fire ... hitting 10 bucks by end of the year.

[Biolandia @valueinvest01]

Go go $IDIA Idorsia .. let's see 10$ by the end of the year

[Altimmune, Inc. @AltimmuneInc]

We’re pleased to share the U.S. FDA has granted Breakthrough Therapy Designation to our investigational treatment for metabolic dysfunction-associated steatohepatitis (MASH).

Learn more: https://t.co/w9QZSj2Dm9

[Monaco @monaco_biotech]

$ALT +15% 📈 pre-market
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH

• BioPharmCatalyst https://t.co/iRtGdtyumG

[Biolandia @valueinvest01]

@monaco_biotech Thoughts ?

[Biolandia @valueinvest01]

@dimitriospaolo you have a lot of text but in the end you say nothing .. my god terrible.

[Biolandia @valueinvest01]

$IDIA Idorsia, maybe it's time to announce a strategic partnership on aprocitentan ??

[Biolandia @valueinvest01]

@monaco_biotech Thoughts ?

[Frank @justfactstruth]

$ARDX Raymond James Strong BUY $14

• What's this - a pipeline? With all the focus on Xphozah's access challenges juxtaposed against ibsrela's out-performance, investors may have overlooked Ardelyx's discovery capabilities. On that note, Ardelyx plans to submit an IND for RDX10531 an NHE3 inhibitor (similar mechanism to tenapanor, but with potentially higher potency and solubility) in 2026.
Although management did not provide any preclinical data or guide to a particular indication for this asset, the literature would argue that this mechanism could be applicable to a wide range of indications including hypertension, heart failure, and diabetes.

Thesis remains intact. We remain Strong Buy rated on Ardely shares with a S14 price target based on continued strength in both Ibsrela and Xphozah sales .
We model FY revenues of 505mm and 613mm for FY 26 and 27

[Michael Green @profplum99]

"We will never again see negative rates"
Switzerland, "Halt mein bier"

[Biolandia @valueinvest01]

Idorsia $IDIA completed an offering of 16.4m shares at 4 CHF per share, raising 65.6m and securing the cash run way.

Yes it's a pullback and a bit of dilution but is for the bigger good. Price will recover and continue it's steady growth. Only good things to come!

[Biolandia @valueinvest01]

@DudeBiotech @SpaceFastighet @Idorsia @IdorsiaUS @RemindMe_OfThis Roche buyout for 5B and we are good

[Biolandia @valueinvest01]

@smmcgonigle @DudeBiotech @Bleeding_Alpha @sled_ @Idorsia @IdorsiaUS @Roche Market sell off last week due to pharma tariff .. is just coming back where it was and continuing to double digits.

[Biolandia @valueinvest01]

@DudeBiotech @cashch @sushiawasabi @Idorsia Super pessimistic and even misleading.

"Idorsia has only two main products on the market: the sleep aid Quviviq and the blood pressure lowering drug Tryvio - with limited potential".

How many products you want from a biotech ? Lol, and by the way these 2 would be enough to rock

[Michel Doepke @doepke_michel]

$IDIA JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension https://t.co/SFoRqaP19R

[Biolandia @valueinvest01]

Idorsia $IDIA rating upgraded from Neutral to Buy with a price target of 6 CHF (up from 2) by H.C. Wainwright.

Double digits we are coming
Cheers

[Biolandia @valueinvest01]

Idorsia $IDIA super strong lately.
Can we see 6/7 CHF per share by end of the year. What are your thoughts??

[Frank @justfactstruth]

$ARDX Morgan Stanley conference wrapping up.
-Original $1B rev guide guide was 10% market share of 550K patients, now the market is 600K and growing double digits. We would hit $1B without any of that market growth.
-Approaching free cash flow positive and our balance sheet now has flexibility and optionality

Closing message CEO Mike Raab
"We don't get the recognition we deserve. We will hit $1B and $750mm revenues and at a $1.5B market cap we are well undervalued"

[Biolandia @valueinvest01]

@SpaceFastighet @DudeBiotech @Vontobel @aktionaer @Idorsia Haha indeed good one.